Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.53 |
| ▸ | ADK | P55263 | 4/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26791255 | 0.92 | SRC (0.53) | SRCADKSLC29A1 | |
| SCHEMBL30403393 | 0.91 | SRC (0.52) | SRCADKSLC29A1 | |
| SCHEMBL26789849 | 0.91 | SRC (0.52) | SRCADKSLC29A1 | |
| SCHEMBL15345547 | 0.84 | SRC (0.53) | SRCADK | |
| SCHEMBL15345551 | 0.84 | SRC (0.53) | SRCADK | |
| SCHEMBL29588478 | 0.82 | SRC (0.48) | SRCADKSLC29A1 | |
| SCHEMBL15345752 | 0.82 | SRC (0.48) | SRCADKSLC29A1 | |
| SCHEMBL26791254 | 0.81 | SRC (0.64) | SRC | |
| SCHEMBL30404376 | 0.80 | SRC (0.63) | SRCADK | |
| SCHEMBL26789846 | 0.80 | SRC (0.63) | SRCADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113271950-B | Pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4197538-A1 | EGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-06-21 | — | — | EP | disclosed |
| EP-4183395-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | SRC 17/4885ADK 2764/4885SLC29A1 658/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | SRC 1373/4885ADK 2393/4885SLC29A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.